Prognostic implications of p21 (Waf1/Cip1) immunolocalization in multiple myeloma

被引:14
作者
Ohata, Masahiko
Nakamura, Shinobu
Fujita, Hiroyuki
Isemura, Mamoru [1 ]
机构
[1] Univ Shizuoka, Dept Cellular Biochem, Grad Sch Nutr & Environm Sci, Yada, Shizuoka 4228526, Japan
[2] Univ Shizuoka, COE 21st, Yada, Shizuoka 4228526, Japan
[3] Shizuoka Red Cross Hosp, Dept Lab Med, Shizuoka 422085, Japan
[4] Nara Med Univ, Dept Gen Med, Nara 6348521, Japan
[5] Shizuoka Red Cross Hosp, Dept Internal Med, Shizuoka 422085, Japan
来源
BIOMEDICAL RESEARCH-TOKYO | 2005年 / 26卷 / 03期
关键词
D O I
10.2220/biomedres.26.91
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Protein p21 (Waf1/Cip1) plays a critical role in controlling the cell cycle especially as a check point of G1 and is intimately associated with important cellular activities including differentiation, senescence, tumorigenesis, and apoptosis. In the present study, we examined the expression of p21 in multiple myeloma (MM) cells for prognostic evaluation. The immunocytochemical localization of p21 could be categorized into nuclear and cytoplasmic types. The nuclear-type p21 localization was correlated with the severity of MM and the expression of proliferating cell nuclear antigen and p53. Patients with the nuclear-type p21 localization survived significantly shorter than those with the cytoplasmic-type localization. Thus, the present study suggests that p21-immunolocalization can be a useful prognostic marker of MM.
引用
收藏
页码:91 / 98
页数:8
相关论文
共 25 条
  • [1] Aoyagi Keishiro, 2003, Kurume Medical Journal, V50, P1
  • [2] Apoptosis inhibitory activity of cytoplasmic p21Cip1/WAF1 in monocytic differentiation
    Asada, M
    Yamada, T
    Ichijo, H
    Delia, D
    Miyazono, K
    Fukumuro, K
    Mizutani, S
    [J]. EMBO JOURNAL, 1999, 18 (05) : 1223 - 1234
  • [3] BATAILLE R, 1984, BLOOD, V63, P468
  • [4] DURIE BGM, 1975, CANCER, V36, P842, DOI 10.1002/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO
  • [5] 2-U
  • [6] Plasmablastic morphology - An independent prognostic factor with clinical and laboratory correlates: Eastern Cooperative Oncology Group (ECOG) myeloma trial E9486 report by the ECOG Myeloma Laboratory Group
    Greipp, PR
    Leong, T
    Bennett, JM
    Gaillard, JP
    Klein, B
    Stewart, JA
    Oken, MM
    Kay, NE
    Van Ness, B
    Kyle, RA
    [J]. BLOOD, 1998, 91 (07) : 2501 - 2507
  • [7] Kanavaros P, 2000, ANTICANCER RES, V20, P4619
  • [8] Low expression of p27 indicates a poor prognosis in patients with high-grade astrocytomas
    Kirla, RM
    Haapasalo, HK
    Kalimo, H
    Salminen, EK
    [J]. CANCER, 2003, 97 (03) : 644 - 648
  • [9] Expression of retinoblastoma gene product and p21 (WAF1/Cip 1) protein in gliomas: correlations with proliferation markers, p53 expression and survival
    Korkolopoulou, P
    Kouzelis, K
    Christodoulou, P
    Papanikolaou, A
    Thomas-Tsagli, E
    [J]. ACTA NEUROPATHOLOGICA, 1998, 95 (06) : 617 - 624
  • [10] Lai R, 1998, MODERN PATHOL, V11, P642